Comparison

Multiple Myeloma [MM] vs ESMO Interactive Guidelines

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

Multiple Myeloma [MM]

This clinical decision support tool provides healthcare professionals with curated, evidence-based medical content for managing Multiple Myeloma. It uses AI-powered natural language queries to deliver quick, confidence-rated answers, aiding in better patient care and outcomes.

Highlights
  • AI-powered natural language queries
  • Evidence-based medical content
  • Diagnosis, treatment, and care management topics
  • Case studies, videos, and interviews
  • Continuing medical education credit
  • Patient education resources
Features
Read full description

@Point of Care™ With Cognitive AI is a clinical decision-making mobile platform. Multiple Myeloma @Point of Care™ provides a streamlined clinical decision support tool for clinicians to obtain content when it is needed—enabling better decisions, better outcomes, and better care. With Cognitive AI, clinicians use @Point of Care™ to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. With Cognitive AI, confidence-rated answers to efficiently incorporate best treatment options happen more quickly and decisions are made faster to improve patient outcomes at the point of care. Multiple Myeloma @Point of Care™ is designed to: • Support discovery and practice change • Provide relevant, evidence-based disease-specific medical content • Improve patient outcomes at the point of care Features: • Continually updated Multiple Myeloma content • Topics in diagnosis, treatment, and care management developed with expert physician authors • Case studies, videos, and interviews • Access to actionable patient-recorded data • Detailed reference list with access to original sources • Continuing medical education credit (CME/CE) • Surveys and peer polling • Patient education resources to share with patients

About

ESMO Interactive Guidelines

Access concise, practical treatment recommendations based on the latest scientific research. This app provides interactive tools, algorithms, and calculators to support healthcare professionals in decision-making and guideline navigation.

Highlights
  • Concise treatment recommendations
  • Interactive decision-making tools
  • Treatment algorithms and calculators
  • Keyword search functionality
  • Bookmarking and note-taking
  • News and push notifications
Features
Read full description

The European Society for Medical Oncology (ESMO) guidelines are developed by experts. They are concise, practical and offer users treatment recommendations that are based on the latest scientific research. This application uses interactive tools to support decision making and help the user navigate the guidelines easily, so they can access the information they require quickly. Each guideline offers best practice recommendations for screening, diagnosis, staging, treatment and follow up. The ESMO Interactive Guidelines application ensures the user has the highest standard of information at their figure tips. A variety of interactive treatment algorithms, tables, calculators and scores can be utilised to assist the treating doctor. The user can also perform key word searches, bookmark useful pages, add notes and email pages to colleagues or patients. The app features news and push notifications. Disclaimer: The app is intended to assist healthcare professionals and allied healthcare professionals as an educational tool to provide information that may support them in providing care to patients. Patients or other community members using this app shall do so only after consultation with a health professional and shall not mistake these guidelines as professional medical advice. These guidelines must not substitute seeking professional medical and health advice from a health professional. These guidelines may not apply to all situations and shall be interpreted in the light of specific clinical situations and resource availability. It is up to every clinician to adapt these guidelines to local regulations and to each patient’s individual circumstances and needs. The app contains information obtained from authentic and highly regarded sources (http://www.esmo.org). Although every effort has been made to ensure that treatment and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician.This application is updated regularly with more tumour types, guidelines and interactive tools.

Screenshots

Multiple Myeloma [MM]4 screens
ESMO Interactive Guidelines4 screens

Verdict

The call

The clearest difference is review sentiment: ESMO Interactive Guidelines at 80% against Multiple Myeloma [MM]'s 50%. ESMO Interactive Guidelines also leads on ratings volume (150 vs 1) and iOS requirement (12.0 vs 14.0). Multiple Myeloma [MM]'s advantage is update cadence (every 5 weeks vs every 6 months) and rating (5.0 vs 4.8). On price, ads, in-app purchases and monetization model there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

Multiple Myeloma [MM] holds the better App Store score, 5.0 against 4.8. That said, the two scores are not equally well evidenced: ESMO Interactive Guidelines has 150 ratings behind it against 1, so its average is the more settled of the two. Written reviews complicate that: 50% of Multiple Myeloma [MM]'s written reviews are positive against 80% of ESMO Interactive Guidelines's, so the app with the better star average is not the one people write more warmly about.

UpkeepUpdate frequency

Multiple Myeloma [MM] ships an update every 5 weeks, ESMO Interactive Guidelines every 6 months. The most recent releases landed on July 17, 2026 and September 11, 2026 respectively.

Scorecard5 real differences · 5 level
Multiple Myeloma [MM] versus ESMO Interactive Guidelines: the parameters behind the verdict, then further details
ParameterMultiple Myeloma [MM]ESMO Interactive Guidelines
PriceFreeFree
Rating5.0 (1 ratings) — better4.8 (150 ratings)
Positive reviews50.0% of reviews80.0% of reviews — better
Number of ratings1150 — better
Update frequencyEvery 5 weeks — betterEvery 6 months
AdsNoNo
In-app purchasesNoNo
MonetizationFreeFree
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS14.012.0 — better
Further details — not scored
Size24 MB195 MB
Age rating12+12+
DeveloperAt Point of Care, LLCEuropean Society for Medical Oncology - ESMO

Customer experience

Multiple Myeloma [MM]

All ratings1 ratings
Positive100.0%
Neutral0.0%
Negative0.0%
Written reviews2 reviews
Positive50.0%
Neutral0.0%
Negative50.0%

ESMO Interactive Guidelines

All ratings150 ratings
Positive96.7%
Neutral2.0%
Negative1.3%
Written reviews5 reviews
Positive80.0%
Neutral0.0%
Negative20.0%

In-app purchases

None

Multiple Myeloma [MM]

No in-app purchases

None

ESMO Interactive Guidelines

No in-app purchases

Questions

Is Multiple Myeloma [MM] free?
Multiple Myeloma [MM] is free to download, with no in-app purchases.
Is ESMO Interactive Guidelines free?
ESMO Interactive Guidelines is free to download, with no in-app purchases.
Which has better reviews, Multiple Myeloma [MM] or ESMO Interactive Guidelines?
Multiple Myeloma [MM] is rated higher. Multiple Myeloma [MM] averages 5.0 out of 5 from 1 ratings, while ESMO Interactive Guidelines averages 4.8 from 150 ratings.
Do Multiple Myeloma [MM] or ESMO Interactive Guidelines have ads?
Neither Multiple Myeloma [MM] nor ESMO Interactive Guidelines shows ads.
Which is updated more often, Multiple Myeloma [MM] or ESMO Interactive Guidelines?
Multiple Myeloma [MM] ships an update every 5 weeks, and ESMO Interactive Guidelines every 6 months. Most recently, Multiple Myeloma [MM] was updated on July 17, 2026 and ESMO Interactive Guidelines on September 11, 2026.

Other comparisons